About Synereca Pharmaceuticals

About company

Synereca Pharmaceuticals, Inc. develops orally active drugs that restore the effectiveness of existing antibiotics. Its portfolio includes prototypic RecA inhibitors, which target various pathogenic bacteria/E. coli, including those responsible for lung, urinary tract, and skin infections, as well as weaponizable gram-positive and gram-negative pathogens through various bactericidal antibiotics. The company was incorporated in 2009 and is based in Chapel Hill, North Carolina.